Table 4.
Late toxicities and treatment factors
| Factor | Hormone-replacement therapya) | Back to school (%)b) | NCF (%)c) | |||
|---|---|---|---|---|---|---|
|
|
|
|
||||
| Positive | p-valued) | Yes | p-valued) | Declined | p-valued) | |
| Treatment | ||||||
|
| ||||||
| RT | 10/19 (52.6) | 0.011 | 25/31 (80.7) | 0.022 | 8/29 (27.6) | 0.002 |
|
| ||||||
| CRT | 22/93 (23.7) | 84/89 (94.4) | 9/121 (7.4) | |||
|
| ||||||
| RT, total dose (Gy) | ||||||
|
| ||||||
| ≤ 50 | 13/57 (22.8) | 0.169 | 47/51 (92.0) | 0.670 | 4/69 (6.0) | 0.051 |
|
| ||||||
| > 50 | 19/55 (34.6) | 62/69 (90.0) | 13/81 (16.0) | |||
|
| ||||||
| WB RT | ||||||
|
| ||||||
| WBRT | 22/52 (42.3) | 0.003 | 56/65 (86.2) | 0.053 | 12/79 (15.2) | 0.116 |
|
| ||||||
| WVRT or IFRT only | 10/60 (16.7) | 53/55 (96.4) | 5/71 (7.0) | |||
|
| ||||||
| WB/WV dose (Gy) | ||||||
|
| ||||||
| ≤ 30 | 12/85 (44.4) | 0.036 | 75/80 (94.0) | 0.120 | 8/111 (7.2) | 0.007 |
|
| ||||||
| > 30 | 20/27 (23.5) | 34/40 (85.0) | 9/39 (23.1) | |||
Values are number/total (%). CRT, radiotherapy with upfront chemotherapy; IFRT, involved-field RT; NCF, severe neurocognitive dysfunction (limitation in daily activities, working or school performance); RT, radiotherapy; WB, whole brain; WV, whole ventricle.
a)
Excluding initial hormone deficiency,
b)
Patients in school-age,
c)
Excluding patients inaccessible to neurocognitive questionnaire in the medical records,
d)
Chi-square test.